PMID- 29905411
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 27
IP  - 7
DP  - 2018 Jul
TI  - Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem 
      cells in a rheumatoid arthritis rat model.
PG  - 873-880
LID - 10.17219/acem/73720 [doi]
AB  - BACKGROUND: Mesenchymal stem cells (MSCs) are of increased importance because of 
      their capacity to counteract inflammation and suppress host immune responses. 
      OBJECTIVES: The aim of the study was to compare the effectiveness of MSCs and 
      hematopoietic stem cells (HSCs) in the treatment of rheumatoid arthritis (RA). 
      MATERIAL AND METHODS: Paw swelling was assessed by measuring the thickness of the 
      hind paws using a caliper. Cytokines - interleukin (IL)-6, tumor necrosis 
      factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta), and IL-10 - and 
      rheumatoid factor (RF) were measured using enzyme-linked immunosorbent assay 
      (ELISA) kits. Oxidative stress biomarkers - malondialdehyde (MDA) and reduced 
      glutathione (GSH) were assessed. Nuclear factor-kappaB (NF-kappaB) was detected by 
      the western blot technique. Toll-like receptor-2 (TLR-2), matrix 
      metalloproteinase-3 (MMP-3) and cartilage oligomeric matrix protein-1 (COMP-1) 
      gene expression were assessed by the real-time quantitative analysis. Mesenchymal 
      stem cells were isolated from the bone marrow (BM) of rats and HSCs were isolated 
      from human umbilical cord blood (UCB). RESULTS: Paw edema, RA score, RF, cytokine 
      assay, antioxidant state, NF-kappaB, TLR-2, MMP3, and COMP-1 showed improvement in 
      the group that received MSCs compared to the group that received HSCs and the 
      group that received methotrexate. CONCLUSIONS: Mesenchymal stem cells are very 
      effective in reducing RA inflammation; they are superior to HSC and methotrexate 
      treatment. Mesenchymal stem cells could become a better therapeutic opportunity 
      for the treatment of RA.
FAU - Abdelmawgoud, Hanan
AU  - Abdelmawgoud H
AD  - Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, 
      Egypt.
FAU - Saleh, Asmaa
AU  - Saleh A
AD  - Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, 
      Egypt.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents
MH  - Antioxidants
MH  - Arthritis, Rheumatoid/*pathology
MH  - Cord Blood Stem Cell Transplantation/*methods
MH  - Disease Models, Animal
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Inflammation/pathology
MH  - Male
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Oxidative Stress/physiology
MH  - Rats
MH  - Rats, Wistar
OTO - NOTNLM
OT  - hematopoietic stem cells
OT  - mesenchymal stem cells
OT  - methotrexate
OT  - rheumatoid arthritis
EDAT- 2018/06/16 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/06/16 06:00
PHST- 2018/06/16 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/06/16 06:00 [entrez]
AID - 10.17219/acem/73720 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2018 Jul;27(7):873-880. doi: 10.17219/acem/73720.